JP4217068B2 - エンドセリンアンタゴニストを用いる癌及び癌関連痛の治療方法 - Google Patents

エンドセリンアンタゴニストを用いる癌及び癌関連痛の治療方法 Download PDF

Info

Publication number
JP4217068B2
JP4217068B2 JP2002517050A JP2002517050A JP4217068B2 JP 4217068 B2 JP4217068 B2 JP 4217068B2 JP 2002517050 A JP2002517050 A JP 2002517050A JP 2002517050 A JP2002517050 A JP 2002517050A JP 4217068 B2 JP4217068 B2 JP 4217068B2
Authority
JP
Japan
Prior art keywords
lower alkyl
bone
alkylene
cancer
abt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2002517050A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004520266A (ja
JP2004520266A5 (cg-RX-API-DMAC10.html
Inventor
ジエイナス，トツド・ジエイ
パドリー，ロバート・ジエイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of JP2004520266A publication Critical patent/JP2004520266A/ja
Publication of JP2004520266A5 publication Critical patent/JP2004520266A5/ja
Application granted granted Critical
Publication of JP4217068B2 publication Critical patent/JP4217068B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Surgery (AREA)
  • Reproductive Health (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2002517050A 2000-08-07 2001-08-06 エンドセリンアンタゴニストを用いる癌及び癌関連痛の治療方法 Expired - Fee Related JP4217068B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63338900A 2000-08-07 2000-08-07
PCT/US2001/024716 WO2002011713A2 (en) 2000-08-07 2001-08-06 Methods of treating bone cancer and the pain associated therewith using endothelin antagonists

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2006302713A Division JP2007084564A (ja) 2000-08-07 2006-11-08 エンドセリンアンタゴニストを用いる癌及び癌関連痛の治療方法
JP2006302712A Division JP2007063288A (ja) 2000-08-07 2006-11-08 エンドセリンアンタゴニストを用いる癌及び癌関連痛の治療方法

Publications (3)

Publication Number Publication Date
JP2004520266A JP2004520266A (ja) 2004-07-08
JP2004520266A5 JP2004520266A5 (cg-RX-API-DMAC10.html) 2007-01-11
JP4217068B2 true JP4217068B2 (ja) 2009-01-28

Family

ID=24539436

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2002517050A Expired - Fee Related JP4217068B2 (ja) 2000-08-07 2001-08-06 エンドセリンアンタゴニストを用いる癌及び癌関連痛の治療方法
JP2006302713A Pending JP2007084564A (ja) 2000-08-07 2006-11-08 エンドセリンアンタゴニストを用いる癌及び癌関連痛の治療方法
JP2006302712A Pending JP2007063288A (ja) 2000-08-07 2006-11-08 エンドセリンアンタゴニストを用いる癌及び癌関連痛の治療方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2006302713A Pending JP2007084564A (ja) 2000-08-07 2006-11-08 エンドセリンアンタゴニストを用いる癌及び癌関連痛の治療方法
JP2006302712A Pending JP2007063288A (ja) 2000-08-07 2006-11-08 エンドセリンアンタゴニストを用いる癌及び癌関連痛の治療方法

Country Status (22)

Country Link
EP (1) EP1347751B1 (cg-RX-API-DMAC10.html)
JP (3) JP4217068B2 (cg-RX-API-DMAC10.html)
KR (1) KR20030027007A (cg-RX-API-DMAC10.html)
CN (1) CN1635878A (cg-RX-API-DMAC10.html)
AR (1) AR031122A1 (cg-RX-API-DMAC10.html)
AT (1) ATE465728T1 (cg-RX-API-DMAC10.html)
AU (2) AU8113401A (cg-RX-API-DMAC10.html)
BG (1) BG107577A (cg-RX-API-DMAC10.html)
BR (1) BR0108865A (cg-RX-API-DMAC10.html)
CA (1) CA2416879C (cg-RX-API-DMAC10.html)
DE (1) DE60141979D1 (cg-RX-API-DMAC10.html)
HU (1) HUP0302977A2 (cg-RX-API-DMAC10.html)
IL (1) IL153769A0 (cg-RX-API-DMAC10.html)
MX (1) MXPA03000984A (cg-RX-API-DMAC10.html)
NO (1) NO20030593L (cg-RX-API-DMAC10.html)
NZ (1) NZ523562A (cg-RX-API-DMAC10.html)
PE (1) PE20020273A1 (cg-RX-API-DMAC10.html)
PL (1) PL366160A1 (cg-RX-API-DMAC10.html)
SK (1) SK1782003A3 (cg-RX-API-DMAC10.html)
TW (1) TWI306760B (cg-RX-API-DMAC10.html)
WO (1) WO2002011713A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA200300253B (cg-RX-API-DMAC10.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0219660D0 (en) 2002-08-23 2002-10-02 Astrazeneca Ab Therapeutic use
GB0403744D0 (en) 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
CN101022826A (zh) * 2004-06-07 2007-08-22 哈罗尔·戴维·贡 用于癌症治疗的细菌组合物
US9107864B2 (en) 2004-06-07 2015-08-18 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
CA2697057A1 (en) 2007-08-22 2009-02-26 Gilead Colorado, Inc. Therapy for complications of diabetes
WO2011114103A1 (en) 2010-03-18 2011-09-22 Biolipox Ab Pyrimidinones for use as medicaments
PL2598165T3 (pl) 2010-07-26 2018-02-28 Qu Biologics Inc. Immunogenne kompozycje przeciwzapalne
CN102485238A (zh) * 2010-12-06 2012-06-06 陈炯华 芎芷镇痛方
CN106456740B (zh) 2014-05-02 2021-06-08 Qu生物制药公司 抗微生物免疫调节

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6063911A (en) * 1993-12-01 2000-05-16 Marine Polymer Technologies, Inc. Methods and compositions for treatment of cell proliferative disorders
ES2259803T3 (es) * 1996-02-13 2006-10-16 Abbott Laboratories Nuevos derivados de pirrolidina sustituidos con benzo-1,3-dioxolilo y benzofuranilo como antagonistas de endostelina.
HUP0003484A3 (en) 1997-08-04 2002-02-28 Abbott Lab Pyrrolidine-3-crboxylic acid derivatives and their use as endothelin antagonists
WO2000036198A1 (en) * 1998-12-11 2000-06-22 Mactapes Limited Curtain heading tape manufacture
US6545048B1 (en) * 1999-06-29 2003-04-08 California Institute Of Technology Compositions and methods of treating cancer using compositions comprising an inhibitor or endothelin receptor activity

Also Published As

Publication number Publication date
AR031122A1 (es) 2003-09-10
CA2416879A1 (en) 2002-02-14
HUP0302977A2 (hu) 2003-12-29
JP2007063288A (ja) 2007-03-15
JP2007084564A (ja) 2007-04-05
IL153769A0 (en) 2003-07-06
EP1347751B1 (en) 2010-04-28
BG107577A (bg) 2003-10-31
AU8113401A (en) 2002-02-18
KR20030027007A (ko) 2003-04-03
ZA200300253B (en) 2004-11-17
PE20020273A1 (es) 2002-04-16
MXPA03000984A (es) 2003-09-05
DE60141979D1 (de) 2010-06-10
SK1782003A3 (en) 2003-08-05
JP2004520266A (ja) 2004-07-08
WO2002011713A2 (en) 2002-02-14
NZ523562A (en) 2006-10-27
WO2002011713A3 (en) 2003-07-17
AU2001281134B2 (en) 2005-06-09
BR0108865A (pt) 2005-04-19
PL366160A1 (en) 2005-01-24
CA2416879C (en) 2006-11-07
EP1347751A2 (en) 2003-10-01
TWI306760B (en) 2009-03-01
ATE465728T1 (de) 2010-05-15
NO20030593D0 (no) 2003-02-06
NO20030593L (no) 2003-02-06
CN1635878A (zh) 2005-07-06

Similar Documents

Publication Publication Date Title
US20050113307A1 (en) Methods of treating cancer and the pain associated therewith using endothelin antagonists
US7576053B2 (en) Methods and compositions for treating degenerative bone disorders
EA029072B1 (ru) Комбинированная терапия, включающая соединение дигидропиразинопиразина и антагонист рецептора андрогена для лечения рака простаты
CA2153213A1 (en) Methods of inhibiting bone loss
CA2416879C (en) Methods of treating cancer and the pain associated therewith using endothelin antagonists
NZ534726A (en) Method for treating cognitive disorders usch as Alzheimer's disease using (+)9-N-phenylcarbinol esroline the (+) isomer of phenserine
JP2001302514A (ja) フェニルエテンスルホンアミド誘導体含有医薬
AU2001281134A1 (en) Methods of treating cancer and the pain associated therewith using endothelin antagonists
RU2320339C2 (ru) Применение анастрозола для лечения женщин в постклимактерическом периоде, которые страдают ранним раком молочной железы
GB2330307A (en) EP4 Receptor antagonists as bone resorption inhibitors
JPWO2005102381A1 (ja) カテプシンｋ阻害薬およびｐｔｈ類を併用することを特徴とする骨密度増加剤
US10463657B2 (en) Method for treating osteoporosis, osteopenia or low bone mineral density
WO2001037876A2 (en) Methods of ameliorating abnormal bone states
JPWO2004035089A1 (ja) ホルモン依存性癌の治療剤
US20050261246A1 (en) Methods for treating inflammatory and autoimmune diseases
CA2555850A1 (en) Methods of treating cancer and the pain associated therewith using endothelin antagonists
JP4454985B2 (ja) 血液脂質を低下させるための医薬組成物
CA2494916A1 (en) Medicinal composition for lowering blood lipid level
WO1997018819A1 (en) Antineoplastic methods and compositions employing optically pure (-)-fotemustine

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20060509

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20060802

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20060810

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20061108

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20081021

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20081107

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20111114

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees